MX2009008323A - Derivados heterociclicos como receptores muscarinicos m3. - Google Patents

Derivados heterociclicos como receptores muscarinicos m3.

Info

Publication number
MX2009008323A
MX2009008323A MX2009008323A MX2009008323A MX2009008323A MX 2009008323 A MX2009008323 A MX 2009008323A MX 2009008323 A MX2009008323 A MX 2009008323A MX 2009008323 A MX2009008323 A MX 2009008323A MX 2009008323 A MX2009008323 A MX 2009008323A
Authority
MX
Mexico
Prior art keywords
muscarinic receptors
heterocyclic derivatives
heterocyclic
derivatives
implicated
Prior art date
Application number
MX2009008323A
Other languages
English (en)
Inventor
Harry Finch
Nicholas Charles Ray
Alan John Nadin
Barbara Giuseppina Avitabile
Jamie David Knight
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0702994A external-priority patent/GB0702994D0/en
Priority claimed from GB0722678A external-priority patent/GB0722678D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of MX2009008323A publication Critical patent/MX2009008323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Esta invención se relaciona con antagonistas M3 de la fórmula (I) donde R2,R4,R5,R6,W,V,A,D,X, t, u y v son como se definió en la presente, las composiciones farmacéuticas que los contienen; los métodos para su preparación; y su uso en el tratamiento de enfermedades donde la activación del receptor M3 reforzada está implicada.
MX2009008323A 2007-02-15 2008-02-14 Derivados heterociclicos como receptores muscarinicos m3. MX2009008323A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0702994A GB0702994D0 (en) 2007-02-15 2007-02-15 Compound and thier use
GB0722678A GB0722678D0 (en) 2007-11-19 2007-11-19 Compounds and their use II
PCT/GB2008/000519 WO2008099186A1 (en) 2007-02-15 2008-02-14 Heterocyclic derivatives as m3 muscarinic receptors

Publications (1)

Publication Number Publication Date
MX2009008323A true MX2009008323A (es) 2009-08-13

Family

ID=39323641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008323A MX2009008323A (es) 2007-02-15 2008-02-14 Derivados heterociclicos como receptores muscarinicos m3.

Country Status (21)

Country Link
US (1) US20100056565A1 (es)
EP (1) EP2121688A1 (es)
JP (1) JP2010519193A (es)
KR (1) KR20090110353A (es)
CN (1) CN101657452A (es)
AR (1) AR065344A1 (es)
AU (1) AU2008215924B2 (es)
BR (1) BRPI0807913A2 (es)
CA (1) CA2676581A1 (es)
CL (1) CL2008000474A1 (es)
CO (1) CO6190612A2 (es)
EC (1) ECSP099573A (es)
IL (1) IL199971A0 (es)
MX (1) MX2009008323A (es)
NZ (1) NZ578489A (es)
PE (1) PE20090357A1 (es)
RU (1) RU2009133258A (es)
SA (1) SA08290066B1 (es)
TW (1) TW200843759A (es)
UY (1) UY30916A1 (es)
WO (1) WO2008099186A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
AU2009282521A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab 2-hydroxy-ethanesulfonate salt
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
KR20170042608A (ko) * 2014-08-26 2017-04-19 아스텔라스세이야쿠 가부시키가이샤 2-아미노티아졸 유도체 또는 그의 염

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88846A0 (en) * 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU2002238471B2 (en) * 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
RU2323218C2 (ru) * 2002-09-30 2008-04-27 НьюроСёрч А/С Новые производные 1,4-диазабициклоалкана и фармацевтическая композиция на их основе
ATE426602T1 (de) * 2002-09-30 2009-04-15 Neurosearch As 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses

Also Published As

Publication number Publication date
AR065344A1 (es) 2009-06-03
JP2010519193A (ja) 2010-06-03
RU2009133258A (ru) 2011-03-20
US20100056565A1 (en) 2010-03-04
CA2676581A1 (en) 2008-08-21
BRPI0807913A2 (pt) 2014-06-17
IL199971A0 (en) 2010-04-15
CO6190612A2 (es) 2010-08-19
AU2008215924A1 (en) 2008-08-21
NZ578489A (en) 2011-05-27
AU2008215924B2 (en) 2011-04-21
WO2008099186A1 (en) 2008-08-21
WO2008099186A8 (en) 2008-11-13
KR20090110353A (ko) 2009-10-21
TW200843759A (en) 2008-11-16
CL2008000474A1 (es) 2008-08-22
EP2121688A1 (en) 2009-11-25
ECSP099573A (es) 2009-12-28
SA08290066B1 (ar) 2011-05-14
CN101657452A (zh) 2010-02-24
UY30916A1 (es) 2008-09-30
PE20090357A1 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
MX2009008323A (es) Derivados heterociclicos como receptores muscarinicos m3.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
MX2009006921A (es) Derivados azaespiro.
RS20080119A (en) Carboxamide derivatives as muscarinic receptor antagonists
TW200740789A (en) Pyridine and pyrimidine derivatives as mGluR2 antagonists
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
MX2013000362A (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
PL1831202T3 (pl) Pochodne pirolidyniowe jako receptory M3 muskarynowe
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
MX2012004112A (es) Derivados de diazepam como moduladores de los receptores de quimiocina.
IL195747A0 (en) Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity
MX2010003986A (es) Antagonistas del receptor 5-ht7.

Legal Events

Date Code Title Description
FG Grant or registration